WARPTECHNEWS · LAB

Home AI Business Tech Archive

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 150 fonti internazionali, con classificazione AI e timeline cluster su singole storie.

Navigazione

Home
Archivio
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Storia: Dr Reddy’s launches oral semaglutide biosimilar Obeda — Warptech Lab News

Storia in 2 fonti

Dr Reddy’s launches oral semaglutide biosimilar Obeda

Dr. Reddy’s launches Obeda, an affordable oral semaglutide biosimilar for type 2 diabetes, enhancing treatment options in India.

Raccontata da

economictimes.indiatimes.com

thehindubusinessline.com

mercoledì 20 maggio 2026·economictimes.indiatimes.com
Dr Reddy's launches oral semaglutide biosimilar Obeda in India
Dr. Reddy's Laboratories proudly presents Obeda, a groundbreaking oral semaglutide biosimilar for managing Type 2 diabetes in India. This innovative treatment offers patients the…
mercoledì 20 maggio 2026·thehindubusinessline.com
Dr Reddy’s launches oral semaglutide biosimilar Obeda
Dr. Reddy’s launches Obeda, an affordable oral semaglutide biosimilar for type 2 diabetes, enhancing treatment options in India.
mercoledì 20 maggio 2026·economictimes.indiatimes.com
Dr Reddy’s launches oral semaglutide in India
Dr Reddys Laboratories has launched its oral semaglutide biosimilar for type 2 diabetes in India. The drug, Obeda, is available in three tablet strengths for daily use. This…